NeoGenomics Inc (FRA:NG9)
€ 12 0 (0%) Market Cap: 1.57 Bil Enterprise Value: 1.78 Bil PE Ratio: 0 PB Ratio: 1.82 GF Score: 76/100

Neogenomics Inc at Bank of America Healthcare Conference Transcript

May 12, 2022 / 04:20PM GMT
Release Date Price: €6.91 (-5.79%)
Derik De Bruin
BofA Securities, Research Division - MD of Equity Research

Good morning, everyone. Welcome to Bank of America's 2022 Healthcare Conference coming to you live from Las Vegas. I'm Derik De Bruin, the Senior Life Sciences and Diagnostic tools analyst from Bank of America. And it is our pleasure to kick off this morning with NeoGenomics.

With me today are Charlie Eidson, IR and Bill Bonello, Chief Financial Officer. Gentlemen, thank you for being here.

William Bishop Bonello
NeoGenomics, Inc. - CFO

Thanks for having us.

Questions & Answers

Derik De Bruin
BofA Securities, Research Division - MD of Equity Research

So get running into it, NEO's had a little bit of rough start in 2022. Your guidance in the summer mutes the management team have transitioned, you've put your hiring plans to hold cost structures and issues, a lot to unpack here. So I think the first question is like why do you think Neo's core business hasn't bounced back as the COVID headwinds have eased like some of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot